What is HC Wainwright’s Estimate for MediWound Q3 Earnings?

MediWound Ltd. (NASDAQ:MDWD) – Stock analysts at HC Wainwright lowered their Q3 2026 earnings per share estimates for shares of MediWound in a report released on Friday, August 14th. HC Wainwright analyst S. Ramakanth now anticipates that the biopharmaceutical company will earn ($0.62) per share for the quarter, down from their previous forecast of ($0.49). HC Wainwright has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for MediWound’s current full-year earnings is ($2.31) per share. HC Wainwright also issued estimates for MediWound’s Q4 2026 earnings at ($0.58) EPS, FY2026 earnings at ($2.02) EPS, Q1 2027 earnings at ($0.55) EPS, Q2 2027 earnings at ($0.57) EPS, Q3 2027 earnings at ($0.47) EPS, Q4 2027 earnings at ($0.42) EPS, FY2027 earnings at ($2.00) EPS, FY2028 earnings at ($0.98) EPS, FY2029 earnings at $0.75 EPS and FY2030 earnings at $2.25 EPS.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.01). The firm had revenue of $3.09 million for the quarter, compared to analyst estimates of $2.59 million. MediWound had a negative net margin of 170.10% and a negative return on equity of 47.24%.

MDWD has been the topic of a number of other reports. Wall Street Zen lowered MediWound from a “sell” rating to a “strong sell” rating in a research note on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediWound in a report on Friday, July 17th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $30.00 target price (down from $32.00) on shares of MediWound in a report on Friday. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, MediWound currently has a consensus rating of “Hold” and an average target price of $33.00.

MediWound Trading Down 1.3%

NASDAQ:MDWD opened at $13.39 on Tuesday. The firm has a market capitalization of $172.06 million, a PE ratio of -7.44 and a beta of 0.15. MediWound has a 1 year low of $13.29 and a 1 year high of $20.30. The firm’s fifty day simple moving average is $14.33 and its 200 day simple moving average is $15.92.

Insider Activity at MediWound

In other MediWound news, Director David Morton Fox purchased 3,537 shares of the business’s stock in a transaction on Monday, June 1st. The stock was purchased at an average price of $14.11 per share, for a total transaction of $49,907.07. Following the completion of the purchase, the director directly owned 22,283 shares in the company, valued at approximately $314,413.13. This trade represents a 18.87% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 9.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Rhumbline Advisers lifted its stake in MediWound by 4.4% in the first quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock valued at $176,000 after acquiring an additional 481 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in shares of MediWound by 69.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 649 shares during the last quarter. BNP Paribas Financial Markets raised its stake in MediWound by 90.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 723 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in MediWound by 22.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 999 shares during the period. Finally, Quarry LP acquired a new position in shares of MediWound in the fourth quarter valued at $26,000. Institutional investors own 46.83% of the company’s stock.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.